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Vaccines provide a primary means to limit disease but may not be effective at blocking infection and pathogen transmission. The
objective of the present study was to evaluate the efficacy of commercial inactivated swine influenza A virus (IAV) vaccines and
experimental live attenuated influenza virus (LAIV) vaccines against infection with H3N2 virus and subsequent indirect trans-
mission to naive pigs. The H3N2 virus evaluated was similar to the H3N2v detected in humans during 2011-2012, which was as-
sociated with swine contact at agricultural fairs. One commercial vaccine provided partial protection measured by reduced nasal
shedding; however, indirect contacts became infected, indicating that the reduction in nasal shedding did not prevent aerosol
transmission. One LAIV vaccine provided complete protection, and none of the indirect-contact pigs became infected. Clinical
disease was not observed in any group, including nonvaccinated animals, a consistent observation in pigs infected with contem-
porary reassortant H3N2 swine viruses. Serum hemagglutination inhibition antibody titers against the challenge virus were not
predictive of efficacy; titers following vaccination with a LAIV that provided sterilizing immunity were below the level consid-
ered protective, yet titers in a commercial vaccine group that was not protected were above that level. While vaccination with
currently approved commercial inactivated products did not fully prevent transmission, certain vaccines may provide a benefit
by limitating shedding, transmission, and zoonotic spillover of antigenically similar H3N2 viruses at agriculture fairs when ad-
ministered appropriately and used in conjunction with additional control measures.
In 2007, human infection with novel influenza A virus (IAV),including swine origin IAV, became a nationally notifiable event
in the United States. Until 2011, reported spillover of IAV from
pigs to people occurred sporadically (three to five reports per year)
and was most often associated with pig exposure (1). In the fall of
2011, approximately 12 cases of variant H3N2 IAV (here H3N2v)
were described, and from July to September of 2012, more than
300 cases were reported, the majority occurring at agricultural
fairs in the summer. This particular H3N2v virus is novel, as it
contains seven gene segments from swine lineage triple-reas-
sortant (tr) H3N2 viruses and the M gene from the 2009 H1N1
pandemic (pH1N1) virus (rH3N2p). However, the H3N2v of
2011-2012 is not the only rH3N2p identified in swine (2–4) in
recent years. In the 1990s in North America, introductions of hu-
man seasonal H3N2 IAV into swine resulted in three genetic vari-
ants ofH3 viruses circulating in swine (clusters I, II, and III) (5, 6).
The H3N2 viruses continued to circulate and evolve, with the
disappearance of clusters I, II, and III and a cluster IV evolving
from cluster III. Cluster IV viruses remain one of the dominant
IAV subtypes identified in the U.S. swine population (7).
Given the frequent spillover events associated with this partic-
ular rH3N2p virus, there is an urgent need to identify methods to
mitigate transmission from pigs to people, as well as among pigs.
IAV vaccines are commonly used in the U.S. swine industry and
provide a likely means to prevent IAV-associated disease. How-
ever, the rapidly evolving diversity of IAV currently circulating in
U.S. swine (8–11) has made controlling IAV with vaccines very
difficult, even with multivalent formulations. While live attenu-
ated influenza virus (LAIV) vaccines have been approved for use
in people and horses, a LAIV for swine has yet to make it to mar-
ket. This is despite a number of LAIV vaccines that have been
developed and demonstrated to provide significant cross-protec-
tion in experimentally infected pigs (12–15).
Most commercial IAV vaccines for pigs are inactivated, multi-
valent formulations using field-sourced IAV as the seed virus, with
each strain reflecting a genetically and antigenically distinct hem-
agglutinin (HA) lineage with possible combinations ofH1, H1,
H1, H11, H12, H1N1pdm09, and/or H3 clusters I to IV. The
present study was designed to evaluate the efficacy of three differ-
ent commercially available swine IAV vaccines and two experi-
mental LAIV vaccines against an rH3N2p virus that is genetically
similar to the H3N2v that spilled over to people in the summer of
2012. In addition, the ability of vaccine immunity to decrease
shedding and limit indirect transmission to naive pigs was evalu-
ated. As noted in a prior pig experiment (16) and again observed
in the present study, rH3N2p virus infection did not cause signif-
icant clinical disease or lung pathology, even in naive pigs. Thus,
clinical presentation is unlikely to be useful for identifying in-
fected pigs. One commercial vaccine provided significant protec-
tion fromnasal shedding of the challenge virus; however, it did not
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completely prevent indirect transmission to naive pigs. One LAIV
provided complete protection against the challenge, as the chal-
lenge virus was not recovered from any principal or contact pig
and the contact pigs did not seroconvert. Taken together, the re-
sults indicate that immunization with a commercial vaccine may
not be sufficient to prevent the transmission of this particular
rH3N2p virus in settings where the population has pigs with
mixed immune statuses. When used appropriately and paired
with other control measures, vaccination may be useful in de-
creasing the amplification of IAV at points of animal concentra-
tion associated with events at which humans and animals inter-
face, ultimately reducing the frequency of spillover.
MATERIALS AND METHODS
Phylogenetic analysis. Representative H3N2 influenza A virus HA se-
quences from contemporary swine field strains and putative vaccine
strains, as well as human H3N2v sequences, were downloaded from the
NCBI GenBank andGISAID EpiFlu databases. Sequences were aligned by
using default settings in MUSCLE v.3.8.31 (17) with subsequent manual
correction in Mesquite, v. 2.75 (http://mesquiteproject.org/mesquite
/mesquite.html). Amaximum-likelihood (ML) tree was inferred by using
the RAxML v7.3.4 program (18), employing a general time-reversible
(GTR) model of nucleotide substitution with  distributed rate variation
among sites. Statistical support for individual nodes within the best-scor-
ing tree was estimated by using the rapid bootstrap algorithm (1,000 rep-
lications) in RAxML v7.3.4.
Vaccines and viruses. Commercial vaccines were procured from vet-
erinary suppliers and administered according to label instructions. KV-1
(FluSure XP; Zoetis) is a fully licensed quadrivalent commercial product
containing the cluster IV H3N2, -cluster H1N1, 1-cluster H1N2, and
2-cluster H1N1 IAVs as vaccine seed viruses. KV-2 (PneumoStar SIV;
Novartis Animal Health, Basel, Switzerland) is a fully licensed bivalent
commercial product containing the cluster I H3N2 and -cluster H1N1
IAVs as vaccine seed viruses. KV-3 (MaxiVac Excell 5.0; Intervet/Sche-
ring-PloughAnimalHealth, Boxmeer, TheNetherlands) is a fully licensed
pentavalent commercial product containing the cluster I and IV H3N2
and-, -, and -cluster H1N1 IAVs as vaccine seed viruses. Both LAIV-1
and LAIV-2 are experimental monovalent vaccines previously described
by our group (12, 13, 19–21). LAIV-1 was derived from a triple-reas-
sortant cluster I H3 virus (A/swine/Texas/4199-2/98 [TX98]) and was
attenuated by engineering a series of stop codons that truncate the non-
structural (ns1) protein, which in turn attenuates the virus’s ability to
antagonize the effects of the host’s type I interferon antiviral response
(22). LAIV-2 was derived from a swine-like triple-reassortant cluster IV
H3 virus (A/turkey/OH/313053/04 [OH04]) and attenuated by introduc-
ing mutations into the polymerase genes, impairing polymerase activity
and restricting virus growth at elevated temperatures (20). A swine isolate
of rH3N2p (A/swine/Indiana/A00968373/2012 [IN12]) that was isolated
from a pig exhibited at a fair and associated with human H3N2v cases in
the summer of 2012 was used as the challenge virus. The virus isolated
from the pigs was genetically similar to the H3N2v viruses isolated from
human cases from the same fair. Wild-type parent virus of each LAIV
strain was used as the antigen in serological assays and representative
cluster I (TX98) and IV (OH04) viruses. LAIV-2, challenge virus, and
viruses used for serological assays were propagated in Madin-Darby ca-
nine kidney (MDCK) cells. LAIV-1 was propagated in 7-day-old embry-
onated chicken eggs incubated for 48 h at 35°C (kindly provided by Mat-
thew Sandbulte, Iowa State University).
Experimental outline. Three-week-old pigs were procured from a
high-health status herd free of influenza and porcine reproductive and
respiratory syndrome viruses and treated with ceftiofur crystalline antibi-
otic (Excede; Zoetis) upon arrival at the National Animal Disease Center.
All pigs were free of IAV and IAV antibodies at the start of the experiment.
At 5 weeks of age, pigs were vaccinated according to the manufacturer’s
recommendations for all of the commercial vaccines—two doses of
FluSureXP andMaxiVac Excell were administered 21 days apart; one dose
of PneumoStar was administered. For experimental LAIV vaccines, pigs
were vaccinated with 2 ml of 106 50% tissue culture infective doses
(TCID50)/ml by the intranasal route twice, 21 days apart. Each principal
vaccinated or nonvaccinated (NV) group included six pigs, and each
group was housed in a separate room. Six weeks following primary vacci-
nation, principal pigs were challenged (Ch) by the intranasal route with 2
ml of 106 TCID50/ml IN12 virus. A group of NV-nonchallenged (NCh)
controls was included. Rectal temperatures were measured daily from the
day before challenge through the day of necropsy for principal pigs. Five
naive, age-matched pigs were placed in a neighboring pen (indirect con-
tact) in each principal room at 2 days postinfection (dpi). Challenged and
indirect-contact pigs were housed in separate raised decks approximately
0.5 m apart. Each deck had solid sides 0.4 m tall and topped with a wire
mesh that prevented the pigs from jumping out of the deck, thus prevent-
ing direct contact. During the 3 days principal and indirect-contact pigs
were housed in the same room, pigs in the indirect-contact pen were
processed and chores involving them (sample collection, feeding, any
handling) were performed first to minimize fomite transfer as much as
possible. Principal pigs were humanely euthanized 3 days after indirect-
contact pigs were placed in the same room at 5 dpi for macroscopic pneu-
monia evaluation, collection of bronchoalveolar lavage fluid (BALF), and
collection of lung tissue for evaluation ofmicroscopic lesions. Nasal swabs
(NS)were collected fromprincipal pigs at 0, 2, 4, and 5 dpi and fromnaive
indirect-contact pigs at 0 to 5, 7, and 9 days postcontact (dpc). Blood was
collected for serum by venipuncture from the principal pigs at the start of
the study (prevaccination), at days 21 and 42 postvaccination, and at
necropsy (dpi 5). Nasal wash (NW) samples were collected from all prin-
cipal pigs on the day of the challenge. Serum samples were collected from
the indirect-contact pigs on the day they were placed in the room with
principal pigs and at necropsy (dpc 0 and 16). Animal studies were con-
ducted in accordance with the National Animal Disease Center’s Institu-
tional Animal Care and Use Committee.
Pathological examination of lungs. At necropsy, the lungs of princi-
pal pigswere removed and the percentage of the lung affectedwith purple-
red consolidation typical of IAV infection was evaluated. The total per-
centage of the entire lung affected (percent pneumonia) was calculated on
the basis of weighted portions of each lobe with respect to the total lung
volume as previously described (23). A portion of the right middle lung
lobe was fixed in 10% buffered formalin for 48 h, processed by routine
histopathologic procedures, and stained with hematoxylin and eosin.Mi-
croscopic lesions were evaluated and scored by a veterinary pathologist
blinded to the treatment groups by using parameters as previously de-
scribed (24).
Viral isolation and titration. NS samples were collected and placed
into 2 ml minimal essential medium (MEM), and BALF samples were
collected by lung lavage with 50 ml of MEM. All samples were stored at
80°C until viral titers were measured at the completion of the animal
study. NS samples were thawed, vortexed, and centrifuged at 300 g for
5 min to pellet debris. Each NS sample was filtered through a 0.45-m
syringe filter, and the fluid was subsequently used for virus isolation and
titration. For virus isolation, 0.2 ml of NS or BALF sample was inoculated
ontoMDCKmonolayers in a 24-well plate, and for virus titration, 10-fold
serial dilutions of sample were inoculated onto MDCK monolayers in
triplicate in a 96-well plate. Samples were incubated for 48 h at 37°C in 5%
CO2. Cells were fixed with 4% phosphate-buffered formalin and stained
by immunocytochemistry with an anti-influenza A virus nucleoprotein
monoclonal antibody (Hb56) as previously described (25). For virus titra-
tion analysis, the (log10-transformed) number of TCID50/ml of each sam-
ple was calculated by the method of Reed andMuench (26). Samples that
were negative on virus titration but positive on virus isolation were as-
signed a value of 0.75 (log10) TCID50/ml. Samples that were negative for
both virus isolation and virus titration were assigned a value of 0.
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Antibody evaluation. For hemagglutination inhibition (HI) antibody
assays, all serum samples were heat inactivated at 56°C for 30 min, subse-
quently treated with a 20% kaolin (Sigma-Aldrich, St. Louis, MO) sus-
pension, and adsorbed with 0.5% turkey red blood cells to remove non-
specific agglutinins. HI antibody titers were determined with 0.5% turkey
red blood cells by using the TX98,OH04, and IN12 viruses as the antigens.
Reciprocal HI antibody titers were divided by 10 and log2 transformed,
analyzed, and reported as the average geometric mean reciprocal titer for
each group.
For evaluation of levels of IgA and IgG antibodies to the rH3N2p
challenge virus, an enzyme-linked immunosorbent assay (ELISA) was
performed. IN12 virus was concentrated over a 20% sucrose cushion and
subsequently used to coat Immulon-2 plates (Nunc) at 50 hemagglutina-
tion units per well. NW and BALF samples were incubated at 1:2 (vol/vol)
with 10 mM dithiothreitol for 1 h at 37°C to dissociate mucus before use
in the ELISA. Serumwas diluted 1:2,000 for IgG evaluation and 1:4 for IgA
evaluation. Horseradish peroxidase-labeled anti-swine IgG (Kirkegaard
and Perry) and anti-swine IgA (Bethyl Laboratories) antibodies were di-
luted 1:1,500 and used as detection antibodies. After substrate addition,
the optical density (OD) at 405 nmwasmeasuredwith an automated plate
reader. Antibody levels are reported as the mean OD of each treatment
group for each antibody isotype (IgA or IgG).
Data analysis. Macroscopic pneumonia scores, microscopic lung
scores, log10-transformed BALF virus titers, and ODs for IgG and IgA
assays were subjected to analysis of variance with P  0.05 considered
significant and a Tukey posttest performed for pairwise comparisons
(GraphPad Prism; GraphPad Software, La Jolla, CA). Log10-transformed
NS virus titers for each time point (dpc) were analyzed by using a mixed
linear model for repeated measures (Proc Mixed, SAS 9.2 for Windows;
SAS Institute, Cary, NC). Linear combinations of the least-squares mean
estimates of NS virus titers were used in a priori contrasts after testing for
a significant (P	 0.05) effect of the vaccine treatment group on NS virus
titers. Comparisons were made between groups at each time point by
using a 5% level of significance (P	 0.05) to assess statistically significant
differences. The correlation between the time (dpc) when a single naive
indirect-contact pig became positive for virus isolation by NS and the
mean viral load of the principal pigs during the time they were cohoused
was determined by calculating the Pearson product-moment correlation
(Proc Corr, SAS 9.2 for Windows; SAS Institute, Cary, NC).
RESULTS
Vaccine strain and challenge strain relatedness. Swine H3 vi-
ruses isolated from 1998 to 2013 form four distinct phylogenetic
clusters, designated I through IV (Fig. 1). As the virus seed strains
used in each of the commercial vaccines are proprietary, phyloge-
netic analysis including the exact vaccine HA genes could not be
performed. However, since vaccine manufacturers indicate the
phylogenetic cluster of the vaccine seed virus, inferences were
made on the basis of representative published sequences from
each cluster and year of isolation. The LAIV-1 and LAIV-2 vac-
cines are cluster I and IV viruses, respectively, and are identified by
solid squares in Fig. 1. The challenge strain is a cluster IV virus
identified by a solid diamond in Fig. 1. Although the LAIV-2 and
IN12 challenge viruses are both within the monophyletic cluster
IV clade, they are highly divergent within that clade (96.3% amino
acid identity). The LAIV-1 and IN12 challenge virus HAs show
89.9% amino acid sequence identity.
HI cross-reactivity following vaccination. Serum was col-
lected from all vaccinated pigs on the day of challenge (day 42
following primary immunization) to evaluate titers ofHI antibod-
ies to representative cluster I (TX98) and cluster IV (OH04) H3
viruses and the rH3N2p challenge virus (IN12) (Table 1). Vacci-
nation with KV-1 and KV-3 resulted in significant titers of HI
antibodies to IN12 challenge virus. KV-2 vaccination induced se-
roconversion, to the cluster I TX98 virus, but the average titer of
antibody to IN12 was less than 20. LAIV vaccination did not in-
duce titers ofHI antibodies to IN12 of greater than 40, but the titer
of HI antibody to each respective homologous antigen was greater
than 40. The KV-3 vaccine, which includes a cluster I and a cluster
IVH3N2 virus, induced significant titers of HI antibodies (
120)
to all three of the antigens tested, although the titers of antibody to
the cluster I virus (TX98) were highest. None of the NV pigs sero-
converted (data not shown).
Protection against rH3N2p challenge following vaccination.
Six weeks following primary immunization, pigs in the principal
groups were challenged intranasally with IN12 and necropsied 5
days later to evaluate lung viral titers and pathology. A group of
NV pigs were included as controls. Four of the five vaccines tested
provided significant protection against viral replication in the
lungs, although the amount of virus recovered varied between the
groups (Fig. 2A). LAIV-2 provided complete protection, as virus
was not recovered from the lungs of any pig. LAIV-1 and KV-1
provided significant protection, as virus was recovered from the
lungs of only two of six pigs in each group and the average virus
titers were less than 1.75 TCID50 (log10). While there was a signif-
icant reduction in the average lung viral titer in KV-3-vaccinated
pigs, there was a wide range of amounts of virus recovered within
the group, from no virus isolated to a titer of 5.25 TCID50/ml
(log10). One commercial vaccine, KV-2, did not provide protec-
tion from viral replication in the lungs, as mean titers were not
significantly different from the mean titer of the NV group (4.7
0.7 versus 5.3 0.4 TCID50 [log10], respectively).
Challenge with the rH3N2p virus, even in NV pigs, did not
induce any obvious clinical disease, such as anorexia or fever (data
not shown). In addition, there were no significant differences in
macroscopic or microscopic pneumonia at 5 dpi between the
NV-Ch andNV-NCh groups (Fig. 2B andC). Thus, while the viral
load in the lungwas significantly different between vaccine groups
at 5 dpi, this was not correlated with significant pathological
changes in the lung (Fig. 2).
Shedding dynamics following challenge of vaccinated prin-
cipal pigs and indirect contact with naive pigs. To test whether
vaccination could prevent or limit transmission, this study in-
cluded an evaluation of viral titers in NS from principal pigs, as
well as naive pigs placed in the same room (indirect contact) as
vaccinated-challenged pigs. When naive, indirect-contact pigs
were placed in the room at 2 dpi, there were significant differences
in the NS viral titers of principal pigs in the different vaccine
groups (Fig. 3A). Vaccination with neither KV-2 nor KV-3 re-
duced virus replication in the nose, as there was no significant
difference in NS titers between the NV group and the KV-2 or
KV-3 group at dpi 2 or dpi 4 or 5. Vaccinationwith LAIV-1 did not
significantly reduce NS titers on dpi 2 or 4, but by dpi 5, there was
a significant reduction in NS virus titers compared to those of the
NV group. Vaccination with KV-1 significantly reduced viral rep-
lication in the nose, as the average titer in NS samples was signif-
icantly reduced by 4 to 5 log10 TCID50 (Fig. 2A) and virus was
isolated from only three of the six pigs in that group (Table 2).
Virus was not isolated from the NS of any pig vaccinated with
LAIV-2, indicating complete protection against the challenge.
The time (dpc) at which naive, indirect-contact pigs had a pos-
itive NS virus isolation was inversely correlated with the average
NS titer (dpi 2, 4, and 5 combined) of the principal pigs (Fig. 3 and
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Table 3). Three of five naive pigs in indirect contact with NV-Ch
pigswere positive for virus in theNSby dpc 1, and all five pigswere
positive by dpc 2. As noted above, vaccination with KV-1 signifi-
cantly reducedNS titers in principal pigs following a challenge and
virus was not recovered from any pigs with indirect contact with
KV-1–Ch pigs until 4 dpc. In contrast, there was no significant
difference in NS virus titers between KV-3 and NV principal pigs,
and by 1 dpc, one indirect naive contact in the KV-3 group was
shedding virus. Virus was not isolated from any pig in the group
with indirect contact with the LAIV-2-vaccinated pigs.
Once a single pig in the indirect-contact pen became infected
and began shedding virus, direct transmission between naive pen-
TABLE 1 Geometric mean reciprocal titers of HI antibodies to different
viral antigens in sera collected 6 weeks following priming
Vaccine groupa
Geometric mean reciprocal titer of HI antibody to
viral antigen:b
IN12 (IV) OH04 (IV) TX98 (I)
KV-1 453 226 28
KV-2 18 28 71
KV-3 143 127 320
LAIV-1 10 13 71
LAIV-2 36 113 10
a See Materials and Methods for full descriptions of the vaccines used.
b The virus used as the antigen in the assay is shown. The H3 phylogenetic cluster is
shown in parentheses.
FIG 1 Phylogeny of representative H3N2 influenza A virus isolates on the basis of the HA-encoding gene. The tree shown was constructed by the ML method
and a GTR substitution model implemented in RAxML v.7.3.4. Values above or below branches indicate bootstrap support (percent) estimated from 1,000
resamplings of the sequence data; bootstrap values of50% are not shown. H3N2HA sublineages are indicated by the brackets on the right (clusters I, II, II, and
IV). Taxon names indicate viral isolates, followed by GenBank or GISAID EpiFlu accession numbers in parentheses. LAIV vaccine isolates are marked with solid
squares, and the challenge virus is marked with a solid diamond. The scale bar indicates the number of nucleotide substitutions per site.
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mates in the contact group occurred. In the KV-1 indirect-contact
group, the first contact pig was positive on dpc 4 and that same pig
was negative for virus by dpc 9. In theNV-Ch group, the first naive
indirect contact was positive by dpc 1 and negative on dpc 9,
indicating a longer duration of infection. In addition, the average
peak NS titer of the KV-1 indirect-contact group was 4.55  0.4
TCID50/ml (log10) on dpc 7; which was significantly less than the
peak titer of the NV indirect-contact group, which was 5.75 0.8
TCID50/ml (log10) on dpc 4 (P	 0.01). Together, these data indi-
cate that the level of exposure to shedding principal pigs had an
impact on the kinetics of viral replication and subsequent shed-
ding in naive, indirect-contact pigs.
Antibody responses following vaccination and challenge.To
further understand the cross-reactive immune response elicited
following vaccination, as well as gain insight into the mechanism
of protection, IgA and IgG in serum and NW cross-reactive to the
challenge virus were evaluated. On the day of challenge, 6 weeks
following the primary vaccination, serum and NWwere collected
from all of the vaccinated principal pigs. Serum levels of IgG to the
rH3N2p IN12 challenge virus were significantly higher in KV-1-
and KV-3-vaccinated pigs than in NV pigs (Fig. 4A). There was
not a significant increase in IgG to IN12 in LAIV-vaccinated pigs
compared to the levels in NV pigs, although a trend toward in-
creased IgG was appreciated. In contrast, IgA levels to IN12 in the
NW were highest in LAIV-vaccinated pigs, as both LAIV-1- and
LAIV-2-vaccinated pigs had significantly elevated levels of IgA
cross-reactive to IN12 virus (Fig. 4B).However, IgA to IN12 in the
NWwas not detected in any pig that received one of the commer-
cial killed vaccines (KV). Neither IN12-specific serum IgA nor
NW IgG was detected in any group (data not shown).
Additionally, antibody levels in the BALF collected on dpi 5
were evaluated (Fig. 5). Levels of IgA in the BALF reactive to the
IN12 challenge virusmirrored the IgA levels in theNW, as IgAwas
detected only in the BALF and NW of LAIV-vaccinated pigs (Fig.
5A). While there was a trend toward increased IgA levels in the
BALF of KV-1-vaccinated pigs, the levels were not significantly
higher than those of NV-Ch or NV-NCh pigs. The IN12-reactive
IgG level in the BALF of LAIV-vaccinated pigs was significantly
higher than that in NV-Ch pigs. The IgG levels in the BALF of
KV-1 pigs were significantly higher than the levels in NV-Ch pigs,
but the levels were not significantly increased in the BALF of
KV-2- or KV-3-vaccinated pigs (Fig. 5B).
FIG 2 Lung viral titers and pathology following primary challenge of vaccinated pigs. Groups of pigs were vaccinated with commercial killed swine IAV vaccine
(KV) or experimental LAIV vaccine or sham vaccinated (NV) as described in Materials and Methods. Six weeks following primary immunization, pigs were
intranasally challenged with rH3N2p virus and their lungs were collected at 5 dpi for evaluation of viral titers in BALF (A) andmacroscopic (B) andmicroscopic
(C) lung lesions. Each data point represents an individual animal in the vaccine group indicated.
FIG 3 Shedding dynamics following primary inoculation or natural acquisition of rH3N2p virus. Groups of pigs were vaccinated with commercial killed swine
IAV vaccine (KV) or experimental LAIV vaccine or sham vaccinated (NV) as described in Materials and Methods. Six weeks following primary immunization,
pigs in the principal group (A) were challenged intranasally with rH3N2p virus and NS was collected at 2, 4, and 5 dpi for quantification of viral titers. (B) At 2
dpi of principal pigs, naive pigs were placed in the same room as the principal pigs (indirect contact) in each respective vaccine group andNSwas collected at the
indicated time (dpc) for quantification of viral titers. Data are expressed as the mean the standard error of the mean of each group. (C) Indirect correlation
between the average viral titer in the NS of principal pigs (dpi 2, 4, and 5 averaged) and the day on which an NS from an indirect, naive contact was positive for
virus.
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DISCUSSION
Situations in which pigs frommixed sources, and thus withmixed
infection statuses and swine IAV immunological profiles, come
into close contact with humans are unique settings for the poten-
tial interspecies transmission of IAV. Agricultural fairs are one
such venue where pigs and people from multiple sources and lo-
cations concentrate in relatively close proximity, and combined
with the propensity for prolonged exposure, this may facilitate
interspecies transmission. The transmission of IAV is bidirec-
tional, with several reported human-to-swine and swine-to-hu-
man transmission events associated with agricultural fairs (11,
27). In the fall of 2011, there were a limited number of reports of
human IAV infection with a swine origin H3N2 virus, all of which
were epidemiologically linked to exposure to pigs at county fairs.
Through the summer of 2012, the number of cases increased to
more than 300 in North America. The H3N2v virus was charac-
terized as a reassortant (r) H3N2 in which seven genes originated
from swine triple-reassortant IAV and the matrix (M) gene of
pandemic (p) H1N1 origin (16). While numerous rH3N2p ge-
nome constellations have been identified in IAV isolated from
pigs, this particular gene constellation is the only rH3N2p virus
that has also been associated with zoonotic transmission to people
to date (28).
Serologic studies conducted with the H3N2v viruses indicated
that certain human age groups have purported seroprotection (HI
antibody titers of
40) whereas others do not (29). The presence
of cross-reacting antibodies in those born after 1990 is not surpris-
ing, since the H3N2 originally introduced into swine was most
closely related to human seasonal H3N2 isolated in themid-1990s
(30, 31). However, current human seasonal trivalent influenza
vaccine (TIV) did not boost antibody levels (HI antibody titers) in
individuals with pre-existing antibody to H3N2v virus (32). In
addition, seasonal TIV did not protect again H3N2v infection or
disease in ferrets (33). Thus, if H3N2vwere to establish itself in the
human population by gaining the ability to be transmitted be-
tween people, a new specific vaccine would be needed (32).
Methods to potentially reduce the exposure of people to swine
IAV at agricultural exhibits include veterinary inspections of
swine stock upon entry and/or during the exhibit, strict policies
for the removal of sick pigs, limitation of the time pigs spend at the
exhibit, limitation of movement between exhibits, and improved
hygiene of the stock and human caretakers. Another additional
method to limit the potential for zoonotic transmission is to con-
trol the virus in the swine stock through vaccination.However, the
vaccine must significantly decrease, if not eliminate, the viral bur-
den to decrease shedding and transmission, in addition to protec-
tion from clinical disease and/or lung pathology. Oftentimes, vac-
cination limits disease but does not prevent shedding; thus, the
transmission cycle is not broken. A previous report indicated that
the rH3N2p viruses do not cause overt clinical disease or lung
pathology in pigs (16), and that was true in the present study as
well. In addition, pigs were not reported to display overt signs of
clinical disease when NS at a county fair were collected for an
ongoing surveillance project, despite positive virus isolation (27).
Taken together, these data indicate that clinical presentation is not
a reliable indicator of infection for all IAV strains.
In North America, there are a number of commercial swine
IAV vaccines available, the majority of which contain inactivated
or killed virus (34). Although manufacturers disclose the phylo-
genetic cluster of the seed virus, the strain name and genetic se-
quence are proprietary. In the present study, the commercial in-
activated vaccine with a cluster I H3 (KV-2) failed to protect, as
expected. However, neither of the cluster IV H3 vaccines (KV-1
and KV-3) was fully protective either. A LAIV vaccine encoding a
cluster IV H3 (LAIV-2) and matched 2002 lineage N2 provided
sterilizing immunity against infection, even though the H3 in the
LAIV-2 is highly divergent (96.3% amino acid identity) from
the cluster IV challenge virus (Fig. 1). As the HA sequences of the
cluster IV H3 viruses in KV-1 and KV-3 are proprietary, the ge-
netic relationship to the LAIV-2 or challenge virus HA could not
be determined; thus, it is difficult to determine if genetic differ-
ences could be related to the lack of protection. Although neither
the LAIV-1 nor the KV-2 vaccine containing cluster I H3 viruses
provided sterilizing immunity, the LAIV-1 vaccine was more effi-
cacious than the KV-2 vaccine. Hence, while the antigen in the
vaccine is important to consider for cross-protection, it appears
that the vaccine platform significantly impacts vaccine efficacy.
Our results support previous studies that show better heterolo-
gous immunity with LAIV vaccines than with intramuscular de-
livery of inactivated products (13, 21, 35).
To control IAV in the swine population and potentially reduce
zoonotic events, a vaccine that reduces shedding of the virus is
necessary. We found a correlation demonstrating that the greater
the amount of virus detected in principal pigs during the time of
exposure, the more quickly a single naive indirect-contact pig was
found to be positive for the virus (Fig. 3C). KV-1 provided signif-
icant protection against nasal shedding in principal pigs, and virus
was not isolated from theNS of an indirect-contact pig until 4 dpc,
compared to 1 to 2 dpc with other vaccine groups. We interpret
these data to indicate that while a vaccine may not provide steril-
izing immunity, if it is able to significantly control nasal shedding,
TABLE 3 Numbers of indirect-contact pigs per group positive for virus
in the nose at different times postcontact with challenged pigs in
different vaccine groups
No. of dpca
No. of indirect-contact pigs positive for virus/total in
vaccine group:b
KV-1 KV-2 KV-3 LAIV-1 LAIV-2 NV
0 0/5 0/5 0/5 0/5 0/5 0/5
1 0/5 0/5 1/5 0/5 0/5 3/5
2 0/5 5/5 3/5 1/5 0/5 5/5
3 0/5 5/5 5/5 5/5 0/5 5/5
4 1/5 5/5 5/5 5/5 0/5 5/5
5 5/5 5/5 5/5 5/5 0/5 5/5
7 5/5 5/5 5/5 5/5 0/5 5/5
9 4/5 2/5 5/5 4/5 0/5 0/5
a Numbers of days after indirect contact are shown.
b See Materials and Methods for full descriptions of the vaccines used.
TABLE 2 Numbers of principal pigs per group positive for virus in the
nose at different times postinfection
No. of dpi
No. of pigs positive/total in vaccine group:a
KV-1 KV-2 KV-3 LAIV-1 LAIV-2 NV
0 0/6 0/6 0/6 0/6 0/6 0/6
2 2/6 6/6 5/6 6/6 0/6 6/6
4 3/6 6/6 6/6 5/6 0/6 6/6
5 3/6 6/6 6/6 5/6 0/6 6/6
a See Materials and Methods for full descriptions of the vaccines used.
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it may decrease the likelihood of indirect transmission to naive
pigs. However, this benefit may be further reduced in naive pigs
with nose-to-nose contact. It is likely that once IAV infects a single
naive indirect-contact pig, direct transmission among the naive
pigs in that pen occurred. Work has shown that vaccination does
prevent susceptibility to IAV infection upon exposure to naive,
infected pigs (36). Further work is needed to determine if vacci-
nation of both the principal group and the indirect-contact group
would further limit direct or indirect transmission between pigs.
However, this study shows that vaccination affording partial pro-
tection of a subset of pigs that share air space with naive pigs may
not control IAV shedding and transmission.
HI antibody titer of serum is the typical immune parameter
used as a correlate of protection from influenza, and reciprocal
titers of greater than 40 are usually considered protective. The
homologous H3N2 vaccine antigen for the commercial vaccines
was not available to be used in the HI assay to determine the
antigenic relationship to the challenge virus. Although cross-reac-
tivity with the challenge virus was evident in the HI assay, the
n-fold reduction compared to the homologous reaction would be
the best indicator of antigenic divergence between the vaccine
strain and the challenge strain. The average reciprocal serum HI
antibody titer for the most efficacious vaccine (LAIV-2) was 36.
However, the KV-3 commercial vaccine average reciprocal serum
HI antibody titer was 143 but was only partially protective (Table
1 and Fig. 2). Thus, using serumHI antibody titers as ameasure of
efficacy and cross-protection was misleading. Serum IgG specific
to IN12 challenge virus mirrored serum HI antibody titers, with
levels highest in the KV-1 group, followed by the KV-3 group, and
both of these vaccines contained H3 cluster IV viruses. Virus-
specific IgA in the NW of LAIV-vaccinated children has been
shown to be correlatedwith protection (reviewed in reference 37).
NW IgA specific to IN12 challenge virus was significantly elevated
in both LAIV-vaccinated groups prior to a challenge (Fig. 4B);
FIG 4 Levels of antibodies specific to the rH3N2p challenge virus in the serum and nasal cavities of pigs following vaccination. Groups of pigs were vaccinated
with commercial killed swine IAV vaccine (KV), experimental LAIV vaccine or shamvaccinated (NV) as described inMaterials andMethods. Sixweeks following
primary immunization, samples were collected for evaluation of serum IgG (A) and NW IgA (B) levels. Data are expressed as the mean OD of each group the
standard error of the mean.
FIG 5 Levels of antibodies specific to the rH3N2p challenge virus in BALF 5 days after a challenge. Groups of pigs were vaccinated with commercial killed swine
IAV vaccine (KV) or experimental LAIV vaccine or sham vaccinated (NV), and 6 weeks following primary immunization, the pigs were challenged by the
intranasal route with rH3N2p IAV. Five days following the challenge (Ch), BALF samples were collected and levels of IgG (A) and IgA (B) antibodies to the
challenge viruswere evaluated by ELISA as described inMaterials inMethods.Data are expressed as themeanODof each group the standard error of themean.
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however, a difference between levels in LAIV-1- and LAIV-2-vac-
cinated pigs was not observed, though there was a difference in the
protection afforded by these two vaccines (Fig. 2 and 4B). It is
likely that the IgA detected in the ELISA was cross-reactive to
conserved regions of the IN12 challenge virus. Although the
ELISA evaluates virus-specific antibody levels, it does not evaluate
functional antibody and is less likely to be used to predict protec-
tion.
Overall, our results provide pig owners and agricultural per-
sonnel experimental data for determining the value of commercial
vaccines in providing protection against this particular rH3N2p
virus. None of the commercial vaccines provided complete pro-
tection against nasal shedding, though one significantly decreased
the amount of virus being shed over time. LAIV vaccination of
children has been shown to induce a weak HI antibody response,
and cell-mediated immunity is believed to contribute to LAIV
vaccine efficacy against phylogenetically distant viruses (38, 39).
While antigen matters in a vaccine regardless of the platform, the
LAIV vaccines provided broader heterologous protection and in-
duced a robust mucosal immune response that likely plays a sig-
nificant role in protection from virus replication in the upper
respiratory tract. Further work is needed to identify an assay that
can be used to predict LAIV vaccine efficacy. One concern often
raised with LAIV vaccines is the potential for reversion; however,
LAIV vaccine has been used for nearly a decade in humans and
reversion has not been documented (40).
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